--- title: Diagnostic Precision Blog | cancer description: cancer | A SeraCare blog focused on precision medicine and advanced clinical diagnostics --- [![SeraCare](https://blog.seracare.com/hs-fs/hubfs/0.%20Logos/SeraCare/SeraCare.png?width=400&name=SeraCare.png "SeraCare")](https://www.seracare.com) - [Home](https://blog.seracare.com/ngs) - [About](https://digital.seracare.com/about-blog) - [News and Events](http://www.seracare.com/NewsEvents/NewsCenter/tabid/354/Default.aspx) - [Contact](http://www.seracare.com/Contact/tabid/366/Default.aspx) ## [Diagnostic Precision](https://blog.seracare.com/) A SeraCare blog focused on precision medicine and advanced clinical diagnostics Choose your Article Focus | [NGS](https://blog.seracare.com/ngs) | [Molecular & Serology](https://blog.seracare.com/molecular-serology-blog) ## [AACR 2019 Day Three: Understanding T-cell Therapy for Unique Cancer Mutations](https://blog.seracare.com/ngs/aacr-2019-day-three-understanding-t-cell-therapy-for-unique-cancer-mutations) Category: [cancer](https://blog.seracare.com/ngs/tag/cancer), [AACR](https://blog.seracare.com/ngs/tag/aacr) Posted by [Catherine Huang, PhD](https://blog.seracare.com/ngs/author/catherine-huang-phd) on Apr 4, 2019 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/T-cell%20.jpeg)](https://blog.seracare.com/ngs/aacr-2019-day-three-understanding-t-cell-therapy-for-unique-cancer-mutations) My third day at the AACR Annual meeting was a day of phenomenal presentations. I am struggling to choose just one to tell you about because I attended multiple inspiring, thought-provoking, and even entertaining talks today. I decided to report on the plenary presentation by Steven A. Rosenberg entitled “T-cell therapy targeting unique cancer mutations” because I think this story has the most potential to positively impact patient outcomes. [Read More](https://blog.seracare.com/ngs/aacr-2019-day-three-understanding-t-cell-therapy-for-unique-cancer-mutations) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/aacr-2019-day-three-understanding-t-cell-therapy-for-unique-cancer-mutations#comments-listing) ## [AACR 2019 Day Two: Learning About the Microbiome in Immuno-Oncology](https://blog.seracare.com/ngs/aacr-2019-day-two-learning-about-the-microbiome-in-immuno-oncology) Category: [cancer](https://blog.seracare.com/ngs/tag/cancer), [AACR](https://blog.seracare.com/ngs/tag/aacr) Posted by [Catherine Huang, PhD](https://blog.seracare.com/ngs/author/catherine-huang-phd) on Apr 3, 2019 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/A-speficic-antibody-(yellow)-blocks-the-binding-site-of-PD-1-(red)-on-a-T-cell-to-avoid-the-down-regulation-of-the-immune-system-by-cancer-cells_-1053-1.jpeg)](https://blog.seracare.com/ngs/aacr-2019-day-two-learning-about-the-microbiome-in-immuno-oncology) At the AACR Annual Meeting, I was most excited to attend the major symposium entitled “The Microbiome as an Orchestrator of Immunity and Cancer Immunotherapy,” which featured three highly informative talks. First, Gregory Sonnenberg from Weill Cornell Medicine gave an overview of how the microbiome contributes to immune homeostasis in the intestine. [Read More](https://blog.seracare.com/ngs/aacr-2019-day-two-learning-about-the-microbiome-in-immuno-oncology) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/aacr-2019-day-two-learning-about-the-microbiome-in-immuno-oncology#comments-listing) ## [New Podcast: Target the Tumor Mutational Burden and Pursue Harmonization](https://blog.seracare.com/ngs/podcast-target-the-tumor-mutational-burden-and-pursue-harmonization) Category: [TMB](https://blog.seracare.com/ngs/tag/tmb), [cancer](https://blog.seracare.com/ngs/tag/cancer) Posted by [Melinda Fayette](https://blog.seracare.com/ngs/author/melinda-fayette) on Mar 20, 2019 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/Friends%20LOGO%20PODCAST-1.jpg)](https://blog.seracare.com/ngs/podcast-target-the-tumor-mutational-burden-and-pursue-harmonization) Friends of Cancer Research aims to better understand the impact of assay variation on clinical outcomes, align standards, and define best practices for tumor mutational burden assessment. Harmonization of methods to quantify TMB will facilitate robust biomarker development and optimize clinical utilization and treatment decision-making. [Read More](https://blog.seracare.com/ngs/podcast-target-the-tumor-mutational-burden-and-pursue-harmonization) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/podcast-target-the-tumor-mutational-burden-and-pursue-harmonization#comments-listing) ## [NTRK Fusion Testing for New Therapies](https://blog.seracare.com/ngs/anti-tropomyosin-receptor-tyrosine-kinase-therapies-and-ntrk-fusion-testing-a-new-paradigm-for-identifying-and-managing-a-class-of-rare-pediatric-and-adult-cancer-patients) Category: [NTRK](https://blog.seracare.com/ngs/tag/ntrk), [cancer](https://blog.seracare.com/ngs/tag/cancer), [RNA fusion](https://blog.seracare.com/ngs/tag/rna-fusion) Posted by [Omo Clement, PhD](https://blog.seracare.com/ngs/author/omo-clement-phd) on Feb 6, 2019 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/NTRK_Cancer_Types.jpg)](https://blog.seracare.com/ngs/anti-tropomyosin-receptor-tyrosine-kinase-therapies-and-ntrk-fusion-testing-a-new-paradigm-for-identifying-and-managing-a-class-of-rare-pediatric-and-adult-cancer-patients) Neurotrophic tyrosine receptor kinases (NTRK) can become abnormally fused to other genes resulting in growth signals that can lead to cancer in many organs of the human body. TRK gene fusion-based cancers are rare but present in pediatric and adult cancers such as lung, thyroid, colon, etc. (see, e.g., Figure 1). [Read More](https://blog.seracare.com/ngs/anti-tropomyosin-receptor-tyrosine-kinase-therapies-and-ntrk-fusion-testing-a-new-paradigm-for-identifying-and-managing-a-class-of-rare-pediatric-and-adult-cancer-patients) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/anti-tropomyosin-receptor-tyrosine-kinase-therapies-and-ntrk-fusion-testing-a-new-paradigm-for-identifying-and-managing-a-class-of-rare-pediatric-and-adult-cancer-patients#comments-listing) ## [Developing a Rock-Solid Lung Cancer Assay, Part 2](https://blog.seracare.com/ngs/developing-a-rock-solid-lung-cancer-assay-part2) Category: [NGS](https://blog.seracare.com/ngs/tag/ngs), [cancer](https://blog.seracare.com/ngs/tag/cancer), [Assay Development](https://blog.seracare.com/ngs/tag/assay-development), [Lung Cancer](https://blog.seracare.com/ngs/tag/lung-cancer) Posted by [Yves Konigshofer, PhD](https://blog.seracare.com/ngs/author/yves-konigshofer-phd) on Jul 2, 2018 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/iStock-902874274.jpg)](https://blog.seracare.com/ngs/developing-a-rock-solid-lung-cancer-assay-part2) In a recent post, we discussed key considerations for designing a robust next-generation sequencing (NGS)-based lung cancer assay. Putting those plans into action in the development phase brings forth a new set of challenges. Through our experience developing NGS reference materials and the relationships we’ve built with assay developers of all stripes, we’ve identified those important factors and ways to navigate them. But before you begin designing and optimizing your assay, you should become very familiar with binomial and Poisson distributions and their use because the outcome of many analytical steps can be modeled and explained with them. [Read More](https://blog.seracare.com/ngs/developing-a-rock-solid-lung-cancer-assay-part2) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/developing-a-rock-solid-lung-cancer-assay-part2#comments-listing) ## [How A New Generation of ctDNA Reference Standards Are Enabling the Promise of Precision Medicine](https://blog.seracare.com/ngs/how-a-new-generation-of-ctdna-reference-standards-are-enabling-the-promise-of-precision-medicine) Category: [SeraSeq](https://blog.seracare.com/ngs/tag/seraseq), [liquid biopsy](https://blog.seracare.com/ngs/tag/liquid-biopsy), [NGS](https://blog.seracare.com/ngs/tag/ngs), [cancer](https://blog.seracare.com/ngs/tag/cancer), [ctDNA](https://blog.seracare.com/ngs/tag/ctdna) Posted by [Omo Clement, PhD](https://blog.seracare.com/ngs/author/omo-clement-phd) on Jun 14, 2018 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/ctDNA%20Complete%20blog.png)](https://blog.seracare.com/ngs/how-a-new-generation-of-ctdna-reference-standards-are-enabling-the-promise-of-precision-medicine) An important goal in cancer disease management is early detection. When detected early, disease progression can be significantly mitigated with a plethora of options (targeted therapy, chemotherapy, surgery, etc.) available to medical practitioners, to afford progression free survival and a higher quality of life. A great promise of liquid biopsies is the possibility of early detection of cancer long before clear evidence of lesions and tumor growth observable by imaging or other techniques.1 As proxy for solid tissue biopsies, plasma-based liquid biopsy application is rapidly gaining traction in cancer disease diagnosis, progression, monitoring, and in predicting resistance to treatment options.2 [Read More](https://blog.seracare.com/ngs/how-a-new-generation-of-ctdna-reference-standards-are-enabling-the-promise-of-precision-medicine) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/how-a-new-generation-of-ctdna-reference-standards-are-enabling-the-promise-of-precision-medicine#comments-listing) ## [Developing a Rock-Solid Lung Cancer Assay](https://blog.seracare.com/ngs/developing-a-rock-solid-lung-cancer-assay) Category: [NGS](https://blog.seracare.com/ngs/tag/ngs), [cancer](https://blog.seracare.com/ngs/tag/cancer), [Lung Cancer](https://blog.seracare.com/ngs/tag/lung-cancer), [reference materials](https://blog.seracare.com/ngs/tag/reference-materials) Posted by [Yves Konigshofer, PhD](https://blog.seracare.com/ngs/author/yves-konigshofer-phd) on Mar 15, 2018 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/LungCancer_iStock-837105016.jpg)](https://blog.seracare.com/ngs/developing-a-rock-solid-lung-cancer-assay) Next-generation sequencing (NGS) allows deeper insights than ever before into the human genome and a host of diseases and conditions. So it makes sense that there is a worldwide movement to employ NGS in a growing number of applications. But as the saying goes, with great power comes great responsibility. [Read More](https://blog.seracare.com/ngs/developing-a-rock-solid-lung-cancer-assay) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/developing-a-rock-solid-lung-cancer-assay#comments-listing) ## [CNVs and Tumor Profiling: New CNV Materials for Breast, Lung, and Brain Cancer](https://blog.seracare.com/ngs/cnvs-and-tumor-profiling-new-cnv-specific-reference-material-for-gene-amplifications-in-breast-lung-and-brain-cancer) Category: [NGS](https://blog.seracare.com/ngs/tag/ngs), [cancer](https://blog.seracare.com/ngs/tag/cancer), [reference materials](https://blog.seracare.com/ngs/tag/reference-materials) Posted by [Dana Ruminski Lowe, Ph.D.](https://blog.seracare.com/ngs/author/dana-ruminski-lowe-ph-d-) on Feb 14, 2018 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/Lung-Cancer-Image-iStock-492387248.jpg)](https://blog.seracare.com/ngs/cnvs-and-tumor-profiling-new-cnv-specific-reference-material-for-gene-amplifications-in-breast-lung-and-brain-cancer) Simply described, copy number variations (CNVs) are DNA segments present at a variable copy number in comparison to a normal genome. It was originally thought that a CNV consisted of a region of greater than 1 kilobases, however advances in technology have allowed for identification of CNVs as small as 50 basepairs1. [Read More](https://blog.seracare.com/ngs/cnvs-and-tumor-profiling-new-cnv-specific-reference-material-for-gene-amplifications-in-breast-lung-and-brain-cancer) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/cnvs-and-tumor-profiling-new-cnv-specific-reference-material-for-gene-amplifications-in-breast-lung-and-brain-cancer#comments-listing) ## [With so many options, how do you select the best NGS cancer assay?](https://blog.seracare.com/ngs/with-so-many-options-how-do-you-select-the-best-ngs-cancer-assay) Category: [NGS](https://blog.seracare.com/ngs/tag/ngs), [cancer](https://blog.seracare.com/ngs/tag/cancer), [RNA fusion](https://blog.seracare.com/ngs/tag/rna-fusion), [reference materials](https://blog.seracare.com/ngs/tag/reference-materials) Posted by [Catherine Huang, PhD](https://blog.seracare.com/ngs/author/catherine-huang-phd) on Jan 11, 2018 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/directions-iStock-585777094.jpg)](https://blog.seracare.com/ngs/with-so-many-options-how-do-you-select-the-best-ngs-cancer-assay) Clinical labs must constantly evolve their test offerings in order to support the most recent advances in clinical care. For next-generation sequencing (NGS) tumor profiling assays, there are often multiple commercially available kits with similar claims for gene content and sensitivity, as well as customized solutions. How can you quickly perform an effective evaluation of available assay systems to make a data-driven choice? [Read More](https://blog.seracare.com/ngs/with-so-many-options-how-do-you-select-the-best-ngs-cancer-assay) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/with-so-many-options-how-do-you-select-the-best-ngs-cancer-assay#comments-listing) ## [How Many Target Copies Are Present in Your Plasma DNA Sample?](https://blog.seracare.com/ngs/how-many-target-copies-are-present-in-your-plasma-dna-sample) Category: [liquid biopsy](https://blog.seracare.com/ngs/tag/liquid-biopsy), [cancer](https://blog.seracare.com/ngs/tag/cancer), [Assay Development](https://blog.seracare.com/ngs/tag/assay-development), [ctDNA](https://blog.seracare.com/ngs/tag/ctdna) Posted by [Dale Yuzuki](https://blog.seracare.com/ngs/author/dale-yuzuki) on Jun 15, 2017 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/plasma_dna_Sample_iStock-166539104.jpg)](https://blog.seracare.com/ngs/how-many-target-copies-are-present-in-your-plasma-dna-sample) The field of circulating tumor DNA analysis (ctDNA, also sometimes called in a larger context “liquid biopsy”) holds great promise for monitoring response to cancer treatment, assisting therapeutic choice, monitoring recurrence, and for pre-cancer screening. As such there is a great amount of assay development and ongoing clinical trials; at ClinicalTrials.gov searching for the term "Circulating DNA" you can find over 180 open clinical trials for a wide range of tumor types and interventions. [Read More](https://blog.seracare.com/ngs/how-many-target-copies-are-present-in-your-plasma-dna-sample) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/how-many-target-copies-are-present-in-your-plasma-dna-sample#comments-listing) [All posts](https://blog.seracare.com/ngs/all) [Next](https://blog.seracare.com/ngs/tag/cancer/page/2) ### Subscribe Here!   ### Posts by Tag - [NGS (64)](https://blog.seracare.com/ngs/tag/ngs) - [reference materials (37)](https://blog.seracare.com/ngs/tag/reference-materials) - [clinical genomics (30)](https://blog.seracare.com/ngs/tag/clinical-genomics) - [ctDNA (29)](https://blog.seracare.com/ngs/tag/ctdna) - [cancer (24)](https://blog.seracare.com/ngs/tag/cancer) - [SeraSeq (16)](https://blog.seracare.com/ngs/tag/seraseq) - [cfDNA (14)](https://blog.seracare.com/ngs/tag/cfdna) - [NIPT (12)](https://blog.seracare.com/ngs/tag/nipt) - [RNA fusion (11)](https://blog.seracare.com/ngs/tag/rna-fusion) - [AACR (10)](https://blog.seracare.com/ngs/tag/aacr) - [AMP (10)](https://blog.seracare.com/ngs/tag/amp) - [liquid biopsy (10)](https://blog.seracare.com/ngs/tag/liquid-biopsy) - [FDA (7)](https://blog.seracare.com/ngs/tag/fda) - [ccfDNA (7)](https://blog.seracare.com/ngs/tag/ccfdna) - [LDT (6)](https://blog.seracare.com/ngs/tag/ldt) - [Assay Development (5)](https://blog.seracare.com/ngs/tag/assay-development) - [Reproductive Health (5)](https://blog.seracare.com/ngs/tag/reproductive-health) - [Accuplex (4)](https://blog.seracare.com/ngs/tag/accuplex) - [NTRK (4)](https://blog.seracare.com/ngs/tag/ntrk) - [Non-invasive Prenatal Testing (4)](https://blog.seracare.com/ngs/tag/non-invasive-prenatal-testing) - [QC Challenges (4)](https://blog.seracare.com/ngs/tag/qc-challenges) - [qc management (4)](https://blog.seracare.com/ngs/tag/qc-management) - [Lung Cancer (3)](https://blog.seracare.com/ngs/tag/lung-cancer) - [MRD (3)](https://blog.seracare.com/ngs/tag/mrd) - [New Reference Material (3)](https://blog.seracare.com/ngs/tag/new-reference-material) - [#Quality (2)](https://blog.seracare.com/ngs/tag/quality) - [EGFR (2)](https://blog.seracare.com/ngs/tag/egfr) - [Inherited Disease (2)](https://blog.seracare.com/ngs/tag/inherited-disease) - [Methylated DNA (2)](https://blog.seracare.com/ngs/tag/methylated-dna) - [Minimal Residual Disease (2)](https://blog.seracare.com/ngs/tag/minimal-residual-disease) - [Molecular Pathology (2)](https://blog.seracare.com/ngs/tag/molecular-pathology) - [PGT (2)](https://blog.seracare.com/ngs/tag/pgt) - [QC Management Software (2)](https://blog.seracare.com/ngs/tag/qc-management-software) - [TMB (2)](https://blog.seracare.com/ngs/tag/tmb) - [Women's health (2)](https://blog.seracare.com/ngs/tag/womens-health) - [myeloid cancer reference materials (2)](https://blog.seracare.com/ngs/tag/myeloid-cancer-reference-materials) - [ngs validation (2)](https://blog.seracare.com/ngs/tag/ngs-validation) - [trisomy (2)](https://blog.seracare.com/ngs/tag/trisomy) - [zika virus (2)](https://blog.seracare.com/ngs/tag/zika-virus) - [BioFidelity (1)](https://blog.seracare.com/ngs/tag/biofidelity) - [Breast Cancer (1)](https://blog.seracare.com/ngs/tag/breast-cancer) - [COVID-19 (1)](https://blog.seracare.com/ngs/tag/covid-19) - [Customer Testimonial (1)](https://blog.seracare.com/ngs/tag/customer-testimonial) - [Genomic Testing (1)](https://blog.seracare.com/ngs/tag/genomic-testing) - [HIV (1)](https://blog.seracare.com/ngs/tag/hiv) - [Immuno-Oncology (1)](https://blog.seracare.com/ngs/tag/immuno-oncology) - [PGS (1)](https://blog.seracare.com/ngs/tag/pgs) - [PGT-A (1)](https://blog.seracare.com/ngs/tag/pgt-a) - [Preimplantation genetic testing (1)](https://blog.seracare.com/ngs/tag/preimplantation-genetic-testing) - [QC Reporting (1)](https://blog.seracare.com/ngs/tag/qc-reporting) - [QC data management (1)](https://blog.seracare.com/ngs/tag/qc-data-management) - [Quality Management Systems (1)](https://blog.seracare.com/ngs/tag/quality-management-systems) - [SARS-CoV-2 (1)](https://blog.seracare.com/ngs/tag/sars-cov-2) - [bioinformatics (1)](https://blog.seracare.com/ngs/tag/bioinformatics) - [laboratory training (1)](https://blog.seracare.com/ngs/tag/laboratory-training) - [listeria (1)](https://blog.seracare.com/ngs/tag/listeria) - [methylated (1)](https://blog.seracare.com/ngs/tag/methylated) See all ### Recent Posts **About SeraCare** With over 30 years of experience as a leading partner to global in vitro diagnostics manufacturers and clinical testing laboratories, SeraCare’s clinical genomics technologies enable the promise of precision medicine by helping scientists and clinicians build and implement better clinical genomics assays. [Learn More](http://www.seracare.com/Company/WhoWeAre/tabid/335/Default.aspx)    - - - [Privacy Policy](http://www.seracare.com/PrivacyPolicy/tabid/211/Default.aspx)  |  [Legal Statement ](http://www.seracare.com/LegalStatement/tabid/212/Default.aspx) **Learn More** [Home](http://seracare.com/)  [About Us](http://seracare.com/Company/WhoWeAre/tabid/335/Default.aspx) [News and Events](http://www.seracare.com/NewsEvents/NewsCenter/tabid/354/Default.aspx)  [Blog](https://blog.seracare.com/)  [Contact](http://seracare.com/Contact/tabid/366/Default.aspx)  ![LGC+Marine-logo-FINAL-teal](https://blog.seracare.com/hs-fs/hubfs/1.%20Logos/LGC+Marine-logo-FINAL-teal.png?width=150&name=LGC+Marine-logo-FINAL-teal.png) 37 Birch Street Milford, MA 01757 [508-244-6400](tel:508-244-6400) l [800-676-1881](tel:800-676-1881) [info@seracare.com](mailto:info@seracare.com) ©2017 SeraCare Life Sciences, Inc. - [About SeraCare](http://www.seracare.com/Company/WhoWeAre/tabid/335/Default.aspx) - [Learn More](http://seracare.com/) - 37 Birch Street Milford, MA 01757 - Google Maps - 508-244-6400 - 508-634-3334 Fax - - - ![logo](https://blog.seracare.com/hubfs/logo.png "logo") 37 Birch Street Milford, MA 01757 508-244-6400 508-634-3334 Fax #### Products #### SeraCare #### Support & Resources - NGS & Digital PCR Tools - Controls & Reference Materials - Validation & Qualification Materials - Plasma & Serum Diluents & Derivatives - Cell Culture Reagents - KPL Antibodies & Conjugates - KPL Immunoassay Reagents & Kits - About Us - Careers - Press Releases - News Articles - Quality Systems - Terms & Conditions - Privacy Policy & Legal Statement - Register for an Account - Contact Us - Sign In - Resource Library - FAQs - Scientific Posters - White Papers - Videos